Artificial Intelligence Prediction Tool in Thymic Epithelial Tumors

Launched by ERASMUS MEDICAL CENTER · Mar 4, 2024

Keywords

ClinConnect Summary

This clinical trial is focused on improving the diagnosis and treatment of thymic epithelial tumors, which are rare types of tumors found in the chest. The researchers are developing a tool that uses artificial intelligence (AI) to help doctors better classify these tumors and predict whether they might come back after treatment. This is important because current methods can be inconsistent, leading to some patients receiving too much or too little treatment. By analyzing data from three different locations, the study aims to create more accurate models that assist pathologists in making the right decisions for each patient.

To participate in this study, individuals must have specific types of thymic tumors, such as thymoma or thymic carcinoma, and there must be some uncertainty in their diagnosis. The trial is open to anyone diagnosed with these tumors, regardless of age or gender. Participants can expect to contribute to research that aims to improve treatment outcomes for future patients with similar conditions. Overall, this trial is a step towards ensuring that patients receive tailored treatments that fit their specific diagnosis more accurately.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• Participants with specific diagnoses are eligible for inclusion in the study. The eligible diagnoses include various subtypes of thymoma and thymic carcinoma, specifically:
• • Thymoma A
• • Thymoma AB
• • Thymoma B1
• • Thymoma B2
• • Thymoma B3
• • Thymic Carcinoma
• • Inclusion is based on a consensus diagnosis with a level of agreement less than 70%. This criterion is applied during the training phase of the model.
• Recurrence Criteria:
• • Participants with a documented recurrence outcome within a 5-year period are considered eligible for this aspect of the study. This criterion is primarily applied during the validation phase.